Veristart passed a key clinical trial that shows it can give physicians a better idea of what to do next after the first round of treatment for NSCLC.
Lung cancer specialist Karen Reckamp, M.D., is tired of seeing what the disease does to her patients. It all comes down to a blood test called VeriStrat.
Biodesix’s business model is based on two strands–clinical diagnostics and companion diagnostics; Tests based on the presence or absence of a biomarker.
Pharmaceutical companies are increasingly turning to companion diagnostic tests to determine whether a drug is suitable for a given patient.
Biodesix's Jeffrey Bojar discusses Evolution of Translational Omics: Lessons Learned and the Path Forward and the rigorous framework it provides.
The Human Genome Project was expected to yield substantial benefits in diagnostics. But the genome is only part of the story. mRNA are equally as important.
Choosing second-line therapy on the basis of a protein-expression test modestly improved survival in patients with advanced non-small cell lung cancer.
Trial Shows Biodesix Assay Predicts Breast Cancer Response to Femara (Genetic Engineering News)
Veristrat from Biodesix is an example of a serum-based test used in the clinic that can predict response to a second-line biotherapeutic treatment option.
Molecular diagnostics is heading the way of personalized medicine, aiming to help physicians devise particular treatment plans specific to the patient.